Compare Hilton Hotels Corporation Common Stock (HLT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Novavax Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.51 (market cap $70.82B), while Novavax Inc trades at $7.9 (market cap $1.31B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 54.1× Novavax Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| HLT | NVAX | |
|---|---|---|
Market Cap | $70.82B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $11.19 |
52-Week Low | $256.75 | $6.22 |
Enterprise Value | $83.83B | $889.30M |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $322.51, up 3.7% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $12.04B in 2025 and net income of $1.46B. Recent news highlights labor strikes and executive stock sales, while analyst consensus remains bullish with a $352 price target.
HLT offers growth potential from travel recovery and pipeline expansion, but faces risks from premium valuation (P/E 46.21), rising debt levels, and operational challenges. The stock trades near resistance at $316-$319, requiring strong Q3 earnings to sustain momentum amid mixed technical indicators.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
